Reversal of the renal hyperglycemic memory by targeting sustained tubular p21 expression
Moh’d Mohanad Al‐DabetiD, Khurrum Shahzad, Ahmed ElwakieliD, Alba SulajiD, Stefan KopfiD, Fabian M BockiD, Ihsan Gadi, Silke ZimmermanniD, Rajiv RanaiD, Shruthi KrishnaniD, Dheerendra Gupta, Sumra Nazir, Ronny BaberiD, Markus R. ScholziD, Robert GeffersiD, Peter Rene MertensiD, Peter P. NawrothiD, John H. GriffiniD, Chris DockendorffiD, Shrey KohliiD, Berend Heinrich IsermanniD
Abstract
A major therapeutic obstacle in diabetes mellitus is the metabolic or hyperglycemic memory: the persistence of impaired organ function despite improvement of blood glucose. Therapies reversing the hyperglycemic memory and thus improving already established organ-dysfunction are lacking, but urgently needed considering the increasing prevalence of diabetes mellitus worldwide. Here we show that glucose-mediated changes in gene expression largely persist in diabetic kidney disease (DKD) despite reversing hyperglycemia. The senescence-associated cyclin-dependent kinase inhibitor p21 (Cdkn1a) was the top hit among genes persistently induced by hyperglycemia and was associated with sustained induction of the p53-p21 pathway. Persistent p21 induction was confirmed in various animal models, in several independent human samples and in in vitro models. Tubular p21 expression and urinary p21-levels were associated with DKD severity and remained elevated despite improved blood glucose levels in humans, suggesting that p21 may be a biomarker indicating persistent ("memorized") kidney damage. Glucose-mediated p21 induction and tubular senescence were enhanced in mice with reduced levels of the disease resolving protease activated protein C (aPC). Mechanistically, glucose-induced and sustained tubular p21 expression is linked with demethylation of its promoter and reduced DNMT1 expression. aPC reverses already established p21 expression independent of its anticoagulant function through receptor signaling. Accordingly, new pharmacological approaches specifically mimicking aPC signaling (3K3A-aPC, parmodulin-2) enabled the reversal of glucose-mediated sustained tubular p21 expression, tubular senescence, and DKD. Thus, p21-dependent tubular senescence contributes to the hyperglycemic memory but can be therapeutically targeted. Single sentence summaryaPC signaling targets persistent p21 expression and tubular senescence and reverses the hyperglycemic memory in diabetic kidney disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Claudin-1 Inhibitor PDS-0330 Ameliorates Diabetic Kidney Disease by Suppressing Src/Akt/mTOR Signaling Pathway in Podocytes
Kazuhiko Fukushima, Kenji Tsuji, … Jun Wada·bioRxiv·Dec 26, 2025
- Transient high glucose causes delayed wound healing by the DNMT1-mediated Ang-1/NF-κB pathway
- SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate
Michael S. Balzer, Song Rong, … Nelli Shushakova·BiomoleculesPeer-reviewed·Nov 19, 2020
- The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion in experimental diabetic kidney disease via promotion of endoplasmic reticulum stress
Aowen Zhuang, Felicia Y. T. Yap, … Josephine Maree Forbes·bioRxiv·Jul 22, 2019
- Prorenin from renal tubules is a major driver of diabetic kidney disease
A. Federlein, C. Lehrmann, … F. Schweda·bioRxiv·Sep 26, 2022
- Kidney single-cell transcriptomes uncover SGLT2i-induced metabolic reprogramming via restoring glycolysis and fatty acid oxidation
Ying Shi, Vivek Bhalla·bioRxiv·Oct 31, 2023